Novavax Global Commercial Operations and COVID-19 Vaccine Update
Novavax's COVID-19 vaccine in 2023: competitive product profile for
vaccine choice
Transition to commercial market expected this year
NUVAXOVID™
Dispersion for injection
COVID-19 Vaccine (recombinant, adjuvanted)
Intramuscular use
Novavax COVID-19 Vaccine,
Adjuvanted in the U.S.1
Bivalent or
monovalent
supporting
variant strain
Safe and
effective²
Cross-strain
protection2
Durable immune
response³
Prevention of
infection4
Refrigerator
stable;
competitive dose
presentation
novavax
2.
1. The Novavax COVID-19 Vaccine, Adjuvanted has not been approved or
licensed by the U.S. Food and Drug Administration (FDA). The trade name
Nuvaxovid has not yet been approved by the FDA.
Dunkle, LM et al., 2021. DOI.; Heath, PT et al., 2021. DOI.
3.
4.
Áñez, G et al. IDWeek, Washington, D.C., October 2022.; Dubovsky, F. Third
Quarter 2022 Financial Results & Operational Highlights, November 2022.
Heath, PT et al., 2022. DOI.
© 2023 NOVAVAX. All rights reserved.
9View entire presentation